Theravance Biopharma, Inc.
TBPH
$8.40
$0.010.12%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.18% | 18.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.18% | 18.32% | |||
| Cost of Revenue | 2.00% | -6.89% | |||
| Gross Profit | 22.38% | 76.66% | |||
| SG&A Expenses | 9.64% | -1.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.93% | -3.21% | |||
| Operating Income | 0.81% | 27.28% | |||
| Income Before Tax | 11.07% | 33.96% | |||
| Income Tax Expenses | 148.98% | 102.29% | |||
| Earnings from Continuing Operations | -22.28% | 23.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.28% | 23.18% | |||
| EBIT | 0.81% | 27.28% | |||
| EBITDA | 0.77% | 26.12% | |||
| EPS Basic | -21.63% | 23.65% | |||
| Normalized Basic EPS | -4.71% | 31.21% | |||
| EPS Diluted | -21.63% | 23.65% | |||
| Normalized Diluted EPS | -4.71% | 31.21% | |||
| Average Basic Shares Outstanding | 0.55% | 0.60% | |||
| Average Diluted Shares Outstanding | 0.55% | 0.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
